Papers by N Sattar · AgingResearch.News

The New England Journal of Medicine2 Oct
Survodutide reduces weight in adults with diabetes and obesity
Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.
Randomised trial in 752 peopleSurvodutide
Paper
European Journal of Internal Medicine26 Sep
Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors
ReviewSGLT2 inhibitors
Paper
Diabetes Care21 Sep
Association of Age at Type 1 Diabetes Onset With Survival, Cardiovascular, and Kidney Outcomes: A Nationwide Cohort Study
Study in peoplePopulations
Paper
The Lancet Regional Health Europe11 Sep
Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case-control study
Study in peoplePopulations
Paper

Circulation8 Sep
Macrotroponin Complexes and Risk of Cardiovascular Events
Cohort study of 19,499 peopleCardiovascular events
Paper
Annals of Internal Medicine7 Sep
Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex : A Prospective Cohort Study
Cohort study of 477,876 peoplePopulations
Paper
medRxiv4 Sep
Connecting diet and disease: Using Mendelian randomisation to bridge the gap
Preprint: trial in peopleInterventions
Paper
Circulation31 Aug
Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial
Randomised trial in 12,257 peopleEvolocumab
Paper
medRxiv28 Aug
Associations between adult obesity and mid-life weight change patterns with cardiometabolic health in early old age: Evidence from the 1958 British birth cohort
Preprint: cohort study of 6,309 peoplePopulations
Paper
The Lancet Diabetes & Endocrinology28 Aug
From adiposity to multisystem morbidity: the case for weight loss as disease modification
ReviewWeight loss
Paper
Journal of the Endocrine Society24 Aug
Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome
Cohort study of 54,114 peopleTirzepatide
Paper
Journal of the American College of Cardiology19 Aug
Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)
Randomised trial in 706 peopleHeart failure
Paper
Diabetes, Obesity & Metabolism17 Aug
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Randomised trial in peopleRetatrutide
Paper
EClinicalMedicine15 Aug
Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis
ReviewPopulations
Paper
PLOS One13 Aug
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials
Randomised trial in peopleTirzepatide
Paper
medRxiv11 Aug
Measuring implementation of clinical guidelines through the COVID-19 pandemic, using linked national health records: a national study of type 2 diabetes in England
Preprint: study in peoplePopulations
Paper
European Journal of Preventive Cardiology10 Aug
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity
Randomised trial in 2,539 peopleTirzepatide
Paper
The Lancet Diabetes & Endocrinology8 Aug
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
Trial in 30,787 peopleSemaglutide
Paper
ADA Scientific Sessions 2026 Abstract8 Jun
Achieving at Least 15% Weight Loss within 2 Years of T2D Diagnosis Is Associated with a Lower Long-Term Risk of Micro- and Macrovascular Disease: A UK Cohort Study
Study in peoplePopulations
Paper
ADA Scientific Sessions 2026 Abstract7 Jun
Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial
Trial in peopleInterventions
Paper